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Abstract
Background Pain is a common symptom in patients with
multiple myeloma (MM). Many patients are dependent on
analgesics and in particular opioids, but there is limited infor-
mation on the impact of these drugs and their side effects on
health-related quality of life (HRQoL).
Method In a cross-sectional study, semi-structured interviews
were performed in 21 patients attending the hospital with
symptomatic MM on pain medications. HRQoL was mea-
sured using items 29 and 30 of the European Organisation for
Research and Treatment of Cancer (EORTC) QLQ-C30.
Results Patients were able to recall a median of two (range
0–4) analgesics. They spontaneously identified a median
of two (range 1–5) side effects attributable to their analge-
sic medications. Patients’ assessment of HRQoL based on
the EORTC QLQ-C30 questions 29/30 was mean 48.3
(95 % CI; 38.7–57.9) out of 100. Patients’ assessment of
their HRQoL in the hypothetical situation, in which they
would not experience any side effects from analgesics, was
significantly higher: 62.6 (53.5–71.7) (t test, p=0.001).
Conclusion This study provides, for the first time, evidence
that side effects of analgesics are common in symptomatic
MM and may result in a statistically and clinically significant
reduction of self-reported HRQoL.
Keywords Multiple myeloma . Quality of life . Opioid .
Analgesics . Side effects
Introduction
Multiple myeloma (MM) has an incidence of approximately
60–70 cases per million inhabitants in the UK, with an aver-
age age at diagnosis of 70 years [1]. In recent years, the
prognosis of symptomatic MM has improved dramatically
owing to the advent of intensive treatments with
haematopoietic stem cell transplantation and novel agents,
including proteasome inhibitors and immunomodulatory
drugs; as a result, increasing numbers of patients are surviving
>5–10 years with the disease. Despite this, pain remains a
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common problem due to both osteolytic bone disease and
increasingly treatment emergent peripheral neuropathy [2, 3].
The treatment of pain caused by multiple myeloma first
starts with therapy directed at disease control, using cyto-
toxics, biological targeted drugs, radiotherapy and corti-
costeroids. Bone disease is also managed systemically
using bisphosphonates, which are used principally to re-
duce future skeletal-related morbidity and may also re-
duce pain [4]. In addition, local pain control may be
achieved using vertebroplasty or balloon kyphoplasty for
vertebral fractures and surgical fixation for unstable long
bones or spine [5, 6]. Alongside these tumour-directed
and supportive care measures, most patients with MM
also receive pharmacological analgesic therapy, including
opioid drugs [2, 7].
The recognition of specific side effects of prescribed
analgesics is of great importance in the effective manage-
ment of pain and optimisation of health-related quality of
life (HRQoL) [8]. Weiss et al. (2001) showed that in a large
US survey of 501 patients with terminal cancer, of whom
52 % reported having ‘moderate to severe pain’, additional
pain therapy was only sought by 29 % of them. The
reasons for not seeking additional therapy in terminal can-
cer patients who had been seen by their primary physician
within the previous 4 weeks included: fear of addiction
(37 %), fear of physical side effects (33 %), fear of mental
side effects (34 %) and fear of pills and injections (29 %)
[9]. Whilst some of these concerns represent real hazards
of cancer pain treatment, it has been suggested that the
adoption of a more multimodal pain strategy, with greater
emphasis on the newer opioids, the use of non-opioids
acting on the NMDA receptor and earlier use of non-
pharmacological approaches, could reduce the emergence
of adverse effects and thus improve patient experience [8].
Determining the right balance of analgesic efficacy
against side effects is difficult as it depends on individual
factors including patients’ age, sex, general health, previ-
ous knowledge and health beliefs, as well as dosage [8,
10]. Only patients can weigh the positive effect of pain
relief against the negative side effects. Therefore, the aim
of this study was to determine whether patients with
symptomatic MM could perceive a difference in their
global health-related QoL, with and without analgesic-
related side effects.
Methods
Institutional approval
This study was approved by the Clinical Effectiveness
Unit of the Sheffield Teaching Hospitals Foundation
NHS Trust as a service evaluation.
Aim and objectives
Our main aim was to examine whether patients perceived an
effect on their HRQoL, arising from the side effects they
experienced from their pain medication.
Specific objectives were (1) to identify the medications
used for pain control in symptomatic MM patients and to
measure the extent to which patients could freely recall them,
in contrast to recognising them from a prompt list; (2) to
quantify the side effects of medications taken by MM patients
and to identify to what extent they were able to attribute these
side effects to analgesics; (3) to compare present HRQoL with
hypothetical HRQoL if the identified side effects were
eliminated.
Population
Patients diagnosed with symptomatic MM in a single tertiary
centre were consecutively interviewed between October and
December 2008. To be eligible for the interview, patients had
to be 18 years or older and be able to communicate in English.
In order to focus on patients with significant supportive care
needs, patients who did not use any painmedication other than
paracetamol and/or who were only on bisphosphonates or
corticosteroids for bone disease were excluded. However, in
the included patients, bisphosphonates were accounted for
amongst the pain medication.
Semi-structured interview
A semi-structured interview was developed and piloted,
consisting of questions on pain medication, symptoms and
items 29 and 30 from the European Organisation for Research
and Treatment of Cancer (EORTC) QLQ-C30 which measure
global HRQoL [11]. The full interview schedule is available
as an online supplement.
In the section on pain medication, patients were first
asked open questions to be answered from memory (1)
about the medications they used for pain control, both at
the time of the interview as well as in the past; (2) for
which pain these medications were used; (3) the side
effects which patients experienced as being directly attrib-
utable to the identified analgesic medications; (4) any side
effects whose attribution they were uncertain of; (5)
whether they felt limited in daily activities because of
these side effects; (6) whether they ever discontinued an
analgesic because of its side effects and if so, which side
effect caused them to discontinue the medicine. Only
analgesics used for pain caused directly by myeloma or
by disease-modifying therapy, for example chemotherapy-
induced painful peripheral neuropathy, were considered
relevant. For the patients’ clarity, we included codeine
and co-codamol separately in the medication lists but in
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the results, we combined the responses for these two
medications under ‘codeine’.
After this first section of the interview, patients were shown
prompt lists containing the most common analgesics and their
common side effects. They were asked again about their
history of pain medication and experienced side effects.
Using this procedure, we were able to compare the ability of
patients to recall their analgesics and side effects accurately by
comparing the answers given from memory with the items
they had recognized after being prompted by the lists.
Patients were asked to give their overall opinion re-
garding the presence and influence of side effects of
analgesics on their HRQoL (‘Yes, in a positive way’;
‘Yes, in a negative way’; ‘No, not at all’.) Patients also
answered questions 29 and 30 of the EORTC QLQ-C30
questionnaire, which have responses on a 7-point Likert
scale ranging from 1 (‘very poor overall health/QoL’) to 7
(‘excellent overall health/QoL’). The resulting score can
range from 2 to 14, which was transformed to a 0–100
scale, according to EORTC recommendations. Together,
these two questions capture a highly personal view of the
patients own perception of global HRQoL using an in-
strument that has been translated and validated into 81
languages and has been used in more than 3,000 studies
worldwide [11, 12]. Patients were asked these questions in
two stages: first, for their present situation (which would
have included the impact of any side effects) and next, for
the hypothetical situation in which they were asked to
estimate what their HRQoL would have been, if they did
not experience any of their recognised analgesic side
effects.
The draft interview was pilot-tested with five health
care specialists and one patient representative to assess
applicability and comprehensibility, and adapted accord-
ingly. Subsequently, the adapted questionnaire was
piloted on two members of the North Trent Consumer
Research Panel and finalised after responding to their
feedback.
In the main study, patients were identified from the day
ward, in-patient wards and out-patient clinics. Consecutive
patients were screened to reduce selection bias. Eligible pa-
tients received an information sheet about the procedure and
had the opportunity to ask questions for clarification. They
were recruited to the study after signing an informed consent
form. Interviews were conducted by SS with help from JB.
Statistical analysis
Data were analysed with SPSS, version 15.0. As this was an
observational cross-sectional study, most of the results are
presented as descriptive. To calculate the difference between
global HRQoL-values with and without side effects, Student’s
t tests for paired samples were used.
Results
Sample
Between October and December 2008, 73 MM patients
were approached. Forty-six patients were excluded from
the interview because they did not use any other pain
medica t ion than paracetamol or were only on
bisphosphonates or corticosteroids. Five other patients
declined to take part, because they had already recently
taken part in other studies (n=2); did not feel well enough
to take part (n=2) or for no given reason (n=1). See
CONSORT diagram, Fig. 1.
Twenty-two patients with a mean(SD) time since diagnosis
of 3.3(1.8)years agreed to take part in the interview. Other
patient characteristics are given in Table 1. One patient with-
drew after starting. The interview took a mean(SD) time of
25(7.28)min.
Pain medications
Analgesics were most often used for back or other bony pain
caused by MM. Some patients additionally needed pain relief
for treatment-related neuropathic pain in their lower extremi-
ties. The majority (17/21) were on step 3 of the WHO anal-
gesic ladder, i.e., they were using a ‘strong’ opioid with or
without other non-opioid analgesics. The most frequently
used current pain medications were paracetamol (n=16),
followed by fentanyl patches (n=10) and oxycodone (n=7).
The most frequently previously used drugs were morphine
(n=7), followed by gabapentin (n=6) and codeine (n=6). See
Table 2.
When asked what analgesics they used now and had
previously been using, patients were able to recall a median
of the two (range 0–4) analgesics. When they were prompted
Fig. 1 Patient disposition (CONSORT diagram)
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by a list of common pain medications, they were now able to
recognize a median of the three (range 1–7) analgesics. Only
one patient reported, without prompting, taking a bisphospho-
nate for pain control and none associated the use of cortico-
steroids as an analgesic. With the help of the prompt sheet,
seven patients recalled using or having used bisphosphonates,
while four patients recalled using or having used
corticosteroids.
Side effects
The median number of freely recalled current and past side
effects, attributed to their pain medication, was two (range 1–5).
Patients declared a median of zero (range 0–3) side effects of
unknown origin, which might or might not have been caused by
analgesics.When patients were asked to read through the prompt
sheet with the most common side effects arising from pain
medication, some were now able to identify more, giving a
median of two (range 1–8) side effects as attributed to their
analgesics. They also now identified a further median of one
(range 0–7) side effects of unknown origin. Altogether, the 21
patients reported a range of 52 specific side effects from pain
medication, which could be classified into 18 distinct groups.
Additionally, they mentioned a total of 42 specific side effects of
unknown origin.
The most commonly reported side effects caused by pain
medication were constipation (n=10), dizziness (n=8) and
tiredness/fatigue (n=8). The most common side effects of
unknown origin were constipation (n=8) and increased sweat-
ing (n=5). See Table 3.
The majority of the 52 side effects attributable to pain
medications were rated as severe (n=25), followed by mod-
erate (n=18) and mild (n=9). Out of the 42 side effects of
unknown origin, the majority was rated as moderate (n=16),
followed by mild (n=14) and severe (n=12). See Table 4.
None of the patients mentioned a side effect that is not
known to be potentially related to the prescribed pain
medications [13].
In absolute numbers, fentanyl patches were responsible
for the largest number of reported side effects (n=12 in 11
patients receiving this drug, currently and in the past),
followed by codeine (n=9 in nine patients), morphine (n=
8 in ten patients) and oxycodone (n=5 in seven patients).
In relative numbers, methadone was responsible for the
highest frequency of side effects, with four side effect
reports by the two patients, followed by fentanyl (12 side
effects in 11 patients) and codeine (nine side effects in
nine patients).
Ten patients (48%) reported that, at some point during their
illness, they stopped taking pain medication or had cut down
on the dose of their medication, because of side effects, most
often with codeine (n=3).
Table 1 Patient characteristics
Patients (n=21)
Gender
Male 10
Female 11
Mean age (±SD) in years 65 (9)
Mean time since diagnosis±SD in years 3.3 (1.8)
WHO Performance status
0 0
1 1
2 11
3 7
4 2
Analgesia according to WHO Pain ladder
1 0
2 4
3 17
Number of analgesic drugs used per patient
1 2
2 5
3 8
4 2
>4 4
Table 2 Pain medications used in 21 patients with multiple myeloma: at
present, in the past and cumulative usage
Pain medication At present In the past Cumulative
n % n % n %
Paracetamol 15 71 4 19 19 90
Fentanyl (patch) 10 48 1 5 11 52
Morphine 3 14 7 33 10 48
Oxycodone 7 33 2 10 9 43
Gabapentin 3 14 6 29 9 43
Codeine 3 14 6 29 9 43
Bisphosphonates 7 33 1 5 8 38
Tramadol 3 14 3 14 6 29
Pregabalin 3 14 1 5 4 19
Corticosteroids 2 10 2 10 4 19
Aspirin 2 10 2 10 4 19
Fentanyl (lozenge) 1 5 2 10 3 14
Methadone 2 10 0 0 2 10
Buprenorphine (patch) 2 10 0 0 2 10
Ketamine 1 5 0 0 1 5
Diclofenac 1 5 0 0 1 5
Diamorphine 0 0 1 5 1 5
Dihydrocodeine 0 0 1 5 1 5
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The majority of patients (n=14; 67 %) reported that the
side effects did not prevent them from performing daily activ-
ities, although they often reported a reduced level as compared
to their activities before their illness.
Global health-related quality of life
Eight patients (38 %) thought that the side effects from their
pain medication had a negative impact on their global
HRQoL, whereas 13 patients (62 %) did not think they had
an impact.
The actual current global HRQoL was mean (range)
48.3 (38.7–57.9) out of a 100. The estimated mean
global HRQoL assuming the absence of side effects
from the analgesics was 62.6 (53.5–71.7), the difference
being 14.3 (p=0.001) (see Table 5). A difference of >10
in the EORTC QLQ-C30 scales is regarded as being
clinically significant [14].
Discussion
MM is a chronic malignant disease which is ultimately fatal,
but with recent improvements in disease management, includ-
ing biological therapies and haematopoeitic stem cell trans-
plantation (HSCT), patients can now expect to live for many
years [1]. However, the pain of bone lesions and additional
treatment-emergent complications such as peripheral neurop-
athy can impose a significant burden on survivors [2]. We
have recently shown that even 5 years after diagnosis and after
three lines of treatments, patients reported pain and fatigue as
their most pressing symptoms; pain was neuropathic in half
the subjects [15]. It is now acknowledged in evidence-based
guidelines of MM that supportive care has a significant role in
its management [3].
One of the most important aspects of supportive care in
MM is to provide effective and safe pain relief. The
results of this study suggest that the side effects of anal-
gesics may significantly reduce HRQoL of patients with
symptomatic MM. Thus, despite the intention of support-
ive care to optimise disease management and minimise
side effects, HRQoL may be inadvertently compromised
of the prescription of analgesic medications. These find-
ings concur with the previous cross-sectional studies in
patients which estimated side effects of opioids in mixed
groups of cancer patients. Villars et al. (2007) studied
oncology outpatients with bone metastases and found a
correlation between total dose of opioid and several re-
ported side effects [10]. The majority of their subjects had
solid tumours were having forms of anti-cancer treatment
and less than 60 % had cancer for longer than 1 year.
Subjects studied by Glare et al. (2006) were in a palliative
care programme, had predominantly solid tumours and the
majority (74 %) were of poor performance status (Eastern
Cooperative Oncology Group [ECOG] 3-4) [16]. They
found the side effects rated as ‘moderate to severe’ in this
population to be dry mouth, sedation, anorexia, seating,
constipation, urinary hesitancy and nightmares. We be-
lieve ours is the only study to describe analgesic side
effects in a homogeneous diagnostic group of patients
who were long-term ambulatory survivors of cancer.
Table 3 Side effects of medication in multiple myeloma patients: Those
due to analgesics, those due to unknown medication and cumulative side
effects
Side effects Pain medication Unknown cause Cumulative
n n n
Constipation 10 7 17
Tiredness/fatigue 8 4 12
Dizziness 8 1 9
Drowsiness 5 4 9
Hallucinations 4 1 5
Nausea 1 4 5
Increased sweating 0 5 5
Feeling sad, depressed 3 1 4
Jerky movements 2 2 4
Dry mouth 1 3 4
Vomiting 2 1 3
Loss of interest in sex 1 2 3
Problems passing urine 0 3 3
Itching 1 1 2
ONJ 1 0 1
Flatulence 1 0 1
Withdrawal 1 0 1
Hot flushes 1 0 1
Flu symptoms 1 0 1
Swelling 1 0 1
Indigestion/heartburn 0 1 1
Itching 0 1 1
Skin rash 0 1 1
Total 52 42 94
ONJ Osteonecrosis of the jaw
Table 4 Severity of medication side effects experienced by patients with
multiple myeloma: Side effects from analgesics, from unknown medica-
tion and cumulative side effects
Severity of side effects Pain medication Unknown cause Cumulative
n n n
Mild 9 14 23
Moderate 18 16 34
Severe 25 12 37
Total 52 42 94
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Earlier studies of HRQoL in MM have focused on the
impact of increasingly more intensive disease-modifying
treatments inMM [17, 18]. We found no previous quantitative
studies on the prevalence and impact of adverse effects of
analgesics on HRQoL in this disease. This study has therefore
provided a first insight into the evaluation of HRQoL in
relation to the side effects from analgesics experienced by
patients with symptomatic MM. We found that analgesic side
effects were rated by patients as mostly ‘severe’. It is note-
worthy that although the perceived difference in HRQoL with
and without analgesic side effects was 14.3, which would be
regarded as clinically significant in the literature, this was not
the initial impression from the question “Do the side effects
from your pain medication have an effect on your quality of
life?”. The majority (62 %) replied ‘No’ and only 38 % stated
it had a negative influence. This shows that asking a single
global question with binary responses could give a superfi-
cially reassuring answer, which is belied by more detailed
structured questioning as the use of the EORTC QLQ-C30
items 29+30 showed. Further evidence that HRQoL had in-
deed been affected by analgesic side effects came from the
observation that nearly half the sample had at some time
stopped or reduced analgesic drugs because of them.
Modern medicine offers many solutions and options to bring
this number down, education being the first and foremost of
them [8].
Methadone was the opioid associated with the highest
absolute number of side effects, although this may be skewed
because of the small sample size. Side effects were also
common with fentanyl patches and rather more frequently
with fentanyl than with morphine. This is surprising in view
of systematic reviews and meta-analyses demonstrating that
fentanyl causes significantly less side effects compared with
morphine [19, 20]. Prior to being on fentanyl, patients most
commonly had used morphine and oxycodone. It is possible
that the first exposure to these prior opioids had already
established a memory of side effects in these patients; second,
the commonest reason for switching from morphine or oxy-
codone to fentanyl would have been intolerance to their side
effects; and third, long-term opioid use led to fentanyl doses
being relatively higher. Unfortunately, we did not record doses
of drugs taken currently or in the past.
Consistent with the literature on chronic opioid use, we
found constipation to be the most prevalent side effect. Apart
from its detrimental effect on wellbeing, opioid-induced con-
stipation (OIC) has a significant health economic cost to
society [21]. Unfortunately, the evidence base for current
management of OIC using conventional laxatives is poor
[22]. Only the newer peripherally acting opioid antagonist
drugs have been shown in large double-blind RCTs to be
efficacious without compromising pain control [23].
Other studies have confirmed that analgesics and especially
opioids are associated with significant adverse effects, not
only for cancer and palliative care patients, but also in the
general population and especially in older people [10]. Zhang
et al. (2009) reported from an Australian adverse reaction
(ADR) database that ‘analgesics/antipyretics/anti-inflammato-
ry drugs’ as a class were associated with the second highest
proportion (after cardiovascular agents) responsible for first
time ADR hospital admission, causing 16.4 % of admissions
in people over 60 years [24]. Opioids were responsible for
4.9 % of these admissions in older patients.
Side effects may reduce compliance and therefore effec-
tiveness of analgesic therapy. Gregorian et al. (2010) demon-
strated using adaptive conjoint analysis that patients with both
cancer and non-cancer chronic pain were able to trade off a
degree of pain control against the relative bothersomeness of
opioid-induced side effects [25]. The highest amount of pain
relief that patients were willing to trade off was in the order of
2 points on an 11-point scale with respect to nausea and
vomiting.
We did not find any previous studies that tried to assess the
impact of analgesic side effects on self-reported HRQoL.
Schmier et al. (2002) used a conjoint analysis methodology
to assess the relative utility states of degrees of pain control
balanced by levels of side effects [26]. Interestingly, their
cohort of cancer patients (n=25) reported a mean current
global QoL rating on the EORTC QLQ-C30 of 48.3 (SD;
21), which was exactly the same as the patients reported in
our study, namely mean 48.3 (95% CI; 38.7–57.9). In their
study, patients were able to declare a reduction in utility of 5
points for a change in side effect severity from mild to severe,
with pain control held constant.
Glintborg et al. (2007) have shown that Danish patients’
reports of their drug history corresponded poorly with hospital
pharmacy records for those patients [27]. In that study, pa-
tients reported a median (range) of four (0–14) prescription
drugs whilst pharmacy records gave one (0–11). These pa-
tients failed to report 27 % of drugs they were taking on
admission. Thus, patients’ own recall of drug histories is
unreliable and needs to be corroborated with external records.
We confirm this with our patients under-reporting the number
Table 5 Self-rated overall quality of life in multiple myeloma patients1
HRQoL scores
(95% CI)2
Current–including current medication side-effects 48.3 (38.7–57.9)
Estimated–excluding current medication side-effects 62.6 (53.5–71.7)
1 The difference in means between ‘Including side-effects’ and ‘Exclud-
ing side-effects’ was highly significant, p=0.001 (Student’s t test)
2 Overall health-related quality of life taken from Items 29 (‘Overall
health’) and 30 (‘Overall quality of life’) from European Organisation
for Research and Treatment of Cancer (EORTC) QLQ-C30 on a scale
from 0–100
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of analgesic drugs from memory, compared to checking them
on a prompt list, although we did not match them to pharmacy
records.
Study limitations
This study has a number of limitations, which means the
results should be interpreted cautiously. The first is the small
sample size—further studies with a larger number of patients
will be needed to confirm or refute these findings. Although
we believe the consecutive sampling from haematology clinic,
day ward and in-patients helped to reduce selection bias, we
cannot be sure that the final sample is representative of other
haematology services. Further multi-centre studies would be
needed to ensure generalizability of the findings.
Another limitation is the possibility of interviewer and inter-
viewee bias. To avoid interviewer bias, the interviews were all
conducted by the same two individuals. Interviewee bias was
minimised by selecting consecutive MM patients attending day
ward, out-patients or admitted to the hospital with effectively
only lack of fluency in English being an exclusion factor.
Some patients expressed difficulties in identifying and
distinguishing between side effects caused by pain medica-
tion, disease-directed therapy or symptoms of disease itself.
We used a standardised prompt sheet to aid patients’ recall of
side effects. However, when being faced by the prompt sheet,
some patients may have overestimated them. Similarly, the
use of medication prompt sheets could have led to over-
estimation of recall of previous analgesic drugs. We did not
investigate whether each mentioned side effect matched the
exact drug to which this side effect was attributed, as this
would have been too extensive for the resources of this service
review. Overall, however, because patients seem to be able to
recognize more side effects from a prompt list than they could
freely recall, providing them with a standard screening symp-
tom list when monitoring and assessing their side effects in
clinical follow-up may be useful in providing better routine
supportive care. In future research studies, these problems
could be solved by prospective recording of drugs and side
effects as they emerge. Patients could be asked to keep diaries
to record side effects and their daily impact.
Another possible weakness is that our findings could have
been influenced by other factors such as symptoms of MM
disease progression and co-morbidity that may mimic side
effects of painkillers and thus impact on HRQoL. The number
of patients included in this study was too small to quantify this
problem.
Because we were obtaining drug histories from patients
directly and did not check these against their case-notes and
drug charts, we were unable to collect data on drug doses. In
future studies of analgesic side effects, current drug doses
should be collected as well as information on other non-
analgesic drugs which could be causing side effects that
overlap with analgesic side effects. Furthermore, the study
could have benefited from a control group, e.g., the MM
patients who were excluded because they only used
bisphosphonates, corticosteroids and paracetamol.
We asked patients to compare their current quality of life
with an estimated quality of life if they did not have analgesic
side effects. Only a few patients expressed difficulties in
imagining the scenario in which they had MM, were using
pain medication, but did not experience any side effects.
Ideally, we should have measured self-rated HRQoL prospec-
tively before and after patients started specific analgesic drugs.
However, we believe that for the majority of patients this
approach was able to quantify a realistic estimate—from the
patients’ own perspective—of impact of analgesics on quality
of life.
Conclusion and recommendations
Even when patients’ self-assessment may be clouded by the
effects of MM disease and its treatment and given the diffi-
culty of answering specific questions for some, we can state
with some confidence that analgesic side effects, in spite of the
measures used in supportive care to minimise them, constitute
a major problem in MM management [2, 3]. This service
review indicates that further research using prospective stud-
ies on pain management and side effects of analgesics should
be conducted in patients with MM and also in other diseases
where long-term, and especially opioid, analgesics are used.
This service evaluation can be seen as a semi-quantitative
pilot project which has given sufficient preliminary informa-
tion to justify a larger research study. In order to increase
sample size and therefore generalizability and to tackle many
of the acknowledged limitations, our intensive cross-sectional
interview-based design should be converted to a self-rated
prospective questionnaire-based survey with parallel record-
ing of drugs and doses from pharmacy records.
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